Nanjing Pharmaceutical
Nanjing Pharmaceutical, also known as Nanjing Pharmaceutical Company Limited, is a prominent player in the pharmaceutical industry, headquartered in Nanjing, China. Established in 1995, the company has made significant strides in the development and manufacturing of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong operational presence across Asia and expanding into international markets, Nanjing Pharmaceutical is recognised for its commitment to quality and innovation. The company’s core offerings include generic medications and specialty pharmaceuticals, distinguished by their rigorous adherence to international standards and advanced production techniques. Nanjing Pharmaceutical has achieved notable milestones, positioning itself as a trusted name in the industry, with a focus on enhancing healthcare solutions globally. Its dedication to research and development continues to drive its success in a competitive market.
DitchCarbon Score
How does Nanjing Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nanjing Pharmaceutical's score of 16 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nanjing Pharmaceutical's reported carbon emissions
In 2023, Nanjing Pharmaceutical reported total carbon emissions of approximately 67,632,680 kg CO2e, comprising 4,996,500 kg CO2e from Scope 1, 62,636,180 kg CO2e from Scope 2, and 67,632,680 kg CO2e from Scope 3 emissions. This represents a slight decrease in Scope 1 emissions compared to 2022, where they were about 5,280,740 kg CO2e, and a reduction in Scope 2 emissions from approximately 63,969,770 kg CO2e. However, Scope 3 emissions increased from about 69,250,510 kg CO2e in 2022. Nanjing Pharmaceutical has not disclosed specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests a need for enhanced climate strategies within the pharmaceutical industry, particularly in addressing Scope 3 emissions, which often represent the largest share of total emissions for companies in this sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 4,513,410 | 0,000,000 | 0,000,000 |
| Scope 2 | 55,998,500 | 00,000,000 | 00,000,000 |
| Scope 3 | 60,511,900 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nanjing Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
